Failed ANDA Bioequivalence Studies Haven’t Impacted Review Decisions, FDA Says
Executive Summary
Bioequivalent studies that fail to show bioequivalence between a generic drug and its reference product have not been a factor in ANDA approvals, Barbara Davit, acting director of the Office of Generic Drugs’ Division of Bioequivalence 2, reported at the Generic Pharmaceuticals Association’s fall technical meeting on Oct. 5 in Bethesda, Md.
You may also be interested in...
Generics Joining The 12-Month Stability Data Club, But “When?” Is Big Question
Generic drug sponsors will need to submit six-month and 12-month stability data for their ANDAs under draft guidance being developed by the Office of Generic Drugs.
Generics Joining The 12-Month Stability Data Club, But “When?” Is Big Question
Generic drug sponsors will need to submit six-month and 12-month stability data for their ANDAs under draft guidance being developed by the Office of Generic Drugs.